Related references
Note: Only part of the references are listed.Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia
Pierre Blais et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
Edith M. Koehler et al.
HEPATOLOGY (2016)
Aspirin use is associated with lower indices of liver fibrosis among adults in the United States
Z. Gordon Jiang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression
Lokpal Bhatia et al.
ATHEROSCLEROSIS (2016)
A systems medicine approach to the study of non-alcoholic fatty liver disease
Salvatore Petta et al.
DIGESTIVE AND LIVER DISEASE (2016)
The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations
Marinos Pericleous et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2016)
Weight Loss Results in Significant Improvements in Quality of Life for Patients With Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study
Elliot B. Tapper et al.
HEPATOLOGY (2016)
Diet, Weight Loss, and Liver Health in Nonalcoholic Fatty Liver Disease: Pathophysiology, Evidence, and Practice
Giulio Marchesini et al.
HEPATOLOGY (2016)
Clinical Patterns of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Multicenter Prospective Study
Fabio Piscaglia et al.
HEPATOLOGY (2016)
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
Stefano Ballestri et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Non-alcoholic fatty liver disease and risk of cardiovascular disease
Amedeo Lonardo et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation
Elizabeth M. Brunt
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
Fabio Nascimbeni et al.
BMJ OPEN GASTROENTEROLOGY (2016)
Liver X Receptor Activation Promotes Polyunsaturated Fatty Acid Synthesis in Macrophages Relevance in the Context of Atherosclerosis
Alexis Varin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα
Michiharu Komatsu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2015)
Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice
Wei-Bin Wu et al.
BIOCHIMIE (2015)
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Understanding Nutritional Interventions and Physical Exercise in Non-Alcoholic Fatty Liver Disease
R. Ordonez et al.
CURRENT MOLECULAR MEDICINE (2015)
Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPAR-Dependent Switch From Lipogenesis to Fat Oxidation
Gijs den Besten et al.
DIABETES (2015)
Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes
Hajime Yamazaki et al.
DIABETES CARE (2015)
Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
Amedeo Lonardo et al.
DIGESTIVE AND LIVER DISEASE (2015)
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis
Elena Turola et al.
DISEASE MODELS & MECHANISMS (2015)
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway
Claudia Filozof et al.
DRUGS (2015)
Targeting the FXR Nuclear Receptor to Treat Liver Disease
Brent A. Neuschwander-Tetri
GASTROENTEROLOGY (2015)
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
Rohit Loomba et al.
GASTROENTEROLOGY (2015)
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
Guillaume Lassailly et al.
GASTROENTEROLOGY (2015)
UK guidelines on the management of variceal haemorrhage in cirrhotic patients
Dhiraj Tripathi et al.
GUT (2015)
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis
Siddharth Singh et al.
HEPATOLOGY (2015)
Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States From 2004 to 2009
Zobair M. Younossi et al.
HEPATOLOGY (2015)
Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease
Sahar Mohamed El-Haggar et al.
HEPATOLOGY INTERNATIONAL (2015)
Nonalcoholic Fatty Liver Disease A Systematic Review
Mary E. Rinella
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis
Srinivasan Dasarathy et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2015)
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
Stuart McPherson et al.
JOURNAL OF HEPATOLOGY (2015)
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
Michaela Mueller et al.
JOURNAL OF HEPATOLOGY (2015)
Statin use and non-alcoholic steatohepatitis in at risk individuals
Paola Dongiovanni et al.
JOURNAL OF HEPATOLOGY (2015)
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
Sven Francque et al.
JOURNAL OF HEPATOLOGY (2015)
Current efforts and trends in the treatment of NASH
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2015)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
Michal Pawlak et al.
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis
Jonathan G. Stine et al.
LIVER TRANSPLANTATION (2015)
Cancer Risk in HBV Patients With Statin and Metformin Use A Population-Based Cohort Study
Chang-I. Chen et al.
MEDICINE (2015)
Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells
Jialin He et al.
MOLECULAR CANCER (2015)
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Sungsoon Fang et al.
NATURE MEDICINE (2015)
Transcriptional regulation of hepatic lipogenesis
Yuhui Wang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Liver X receptor β controls thyroid hormone feedback in the brain and regulates browning of subcutaneous white adipose tissue
Yifei Miao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude
Christine Pocha et al.
SEMINARS IN LIVER DISEASE (2015)
Factors associated with significant liver fibrosis assessed using transient elastography in general population
Seng Chan You et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
Xijun Liu et al.
ONCOTARGET (2015)
A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity
Dong-Hyun Kim et al.
EMBO JOURNAL (2015)
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Changtao Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease
Mariana Verdelho Machado et al.
PLOS ONE (2015)
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Amedeo Lonardo et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2015)
PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome
J. Shen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis
Amit G. Singal et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology
P. Loria et al.
ATHEROSCLEROSIS (2014)
Bile acids, obesity, and the metabolic syndrome
Huijuan Ma et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2014)
Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis
Weibin Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
NHE1 deficiency in liver: Implications for non-alcoholic fatty liver disease
Vikram Prasad et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction
Xijun Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver
Woo-Cheol Sim et al.
BIOCHEMICAL PHARMACOLOGY (2014)
FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model
Cindy Kunne et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice
F. A. R. Livero et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2014)
Molecular Pathways: Sterols and Receptor Signaling in Cancer
Linara Gabitova et al.
CLINICAL CANCER RESEARCH (2014)
Expression of Liver X Receptor Correlates with Intrahepatic Inflammation and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Sang Bong Ahn et al.
DIGESTIVE DISEASES AND SCIENCES (2014)
NASH (Nonalcoholic steatohepatitis): A case of multiorganelle failure
Stephen Caldwell
FREE RADICAL BIOLOGY AND MEDICINE (2014)
Increased Intake of Vegetables, But Not Fruit, Reduces Risk for Hepatocellular Carcinoma: A Meta-analysis
Yang Yang et al.
GASTROENTEROLOGY (2014)
Meta-Analysis of Associations Between the Peroxisome Proliferator-Activated Receptor-γ Pro12Ala Polymorphism and Susceptibility to Nonalcoholic Fatty Liver Disease, Rheumatoid Arthritis, and Psoriatic Arthritis
Young Ho Lee et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2014)
Gender and Menopause Impact Severity of Fibrosis Among Patients With Nonalcoholic Steatohepatitis
Ju Dong Yang et al.
HEPATOLOGY (2014)
Effects of Purified Eicosapentaenoic and Docosahexaenoic Acids in Nonalcoholic Fatty Liver Disease: Results From the WELCOME* Study
Eleonora Scorletti et al.
HEPATOLOGY (2014)
The Transrepressive Activity of Peroxisome Proliferator-Activated Receptor Alpha Is Necessary and Sufficient to Prevent Liver Fibrosis in Mice
Michal Pawlak et al.
HEPATOLOGY (2014)
Nonalcoholic Steatohepatitis Is the Most Rapidly Growing Indication for Liver Transplantation in Patients With Hepatocellular Carcinoma in the U. S.
Robert J. Wong et al.
HEPATOLOGY (2014)
Ursodeoxycholic Acid Inhibits Liver X Receptor α-mediated Hepatic Lipogenesis via Induction of the Nuclear Corepressor SMILE
Ji-Min Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Periostin promotes liver steatosis and hypertriglyceridernia through dovvnregulation of PPARα
Yan Lu et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease
Stuart McPherson et al.
JOURNAL OF HEPATOLOGY (2014)
Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice
Xuelian Xiong et al.
JOURNAL OF HEPATOLOGY (2014)
Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: role of PPAR-α and SREBP-1c
Camila G. Dossi et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2014)
Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease
Jaividhya Dasarathy et al.
LIVER INTERNATIONAL (2014)
Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?
Mariana V. Machado et al.
LIVER INTERNATIONAL (2014)
Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity
Gianluigi Mazzoccoli et al.
LIVER INTERNATIONAL (2014)
The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis
Guo-Xiao Wang et al.
NATURE MEDICINE (2014)
Chemopreventive strategies in hepatocellular carcinoma
Siddharth Singh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
The Role of Small Heterodimer Partner in Nonalcoholic Fatty Liver Disease Improvement After Sleeve Gastrectomy in Mice
Andriy Myronovych et al.
OBESITY (2014)
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
Salvatore Petta et al.
PLOS ONE (2014)
Model Steatogenic Compounds (Amiodarone, Valproic Acid, and Tetracycline) Alter Lipid Metabolism by Different Mechanisms in Mouse Liver Slices
Ewa Szalowska et al.
PLOS ONE (2014)
Diabetes Mellitus and Poorer Prognosis in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Yan-Gang Wang et al.
PLOS ONE (2014)
Experimental models of non-alcoholic fatty liver disease in rats
Otto Kucera et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen
Amedeo Lonardo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Liver X receptor activation increases hepatic fatty acid desaturation by the induction of SCD1 expression through an LXRα-SREBP1c-dependent mechanism
Xiaoyan Zhang et al.
JOURNAL OF DIABETES (2014)
Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice
Ja Kyung Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2014)
A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis
Kristine Griffett et al.
ACS CHEMICAL BIOLOGY (2013)
Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States
Tania M. Welzel et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease
Simon Ducheix et al.
BIOCHEMICAL PHARMACOLOGY (2013)
CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth
Kin-Fai Cheung et al.
CANCER (2013)
LXRs Regulate ER Stress and Inflammation through Dynamic Modulation of Membrane Phospholipid Composition
Xin Rong et al.
CELL METABOLISM (2013)
Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player
Lazar A. Bojic et al.
CURRENT OPINION IN LIPIDOLOGY (2013)
Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Amedeo Lonardo et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Activation of PPARα Ameliorates Hepatic Insulin Resistance and Steatosis in High Fructose-Fed Mice Despite Increased Endoplasmic Reticulum Stress
Stanley M. H. Chan et al.
DIABETES (2013)
Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
Bertrand Cariou et al.
DIABETES CARE (2013)
Statins and primary liver cancer: a meta-analysis of observational studies
Danitza Pradelli et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2013)
Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis
Siddharth Singh et al.
GASTROENTEROLOGY (2013)
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
Hsiao-Ping Chen et al.
GUT (2013)
Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Bart Staels et al.
HEPATOLOGY (2013)
Liver and diabetes. A vicious circle
Paola Loria et al.
HEPATOLOGY RESEARCH (2013)
Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?
Lucia Carulli et al.
INTERNAL AND EMERGENCY MEDICINE (2013)
Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
Rachel H. McMahan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Genetic Variation in NR1H4 Encoding the Bile Acid Receptor FXR Determines Fasting Glucose and Free Fatty Acid Levels in Humans
Martin Heni et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS
Elena Maneschi et al.
JOURNAL OF ENDOCRINOLOGY (2013)
From NAFLD in clinical practice to answers from guidelines
Fabio Nascimbeni et al.
JOURNAL OF HEPATOLOGY (2013)
A 360-degree overview of paediatric NAFLD: Recent insights
Valerio Nobili et al.
JOURNAL OF HEPATOLOGY (2013)
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
Raluca Pais et al.
JOURNAL OF HEPATOLOGY (2013)
Lipid Regulators during Atherogenesis: Expression of LXR, PPAR, and SREBP mRNA in the Human Aorta
Tatyana A. Shchelkunova et al.
PLOS ONE (2013)
Ageing Fxr Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASH
Mikael Bjursell et al.
PLOS ONE (2013)
Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
Yongjie Ma et al.
PHARMACEUTICAL RESEARCH (2013)
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
E. Boettcher et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk
Y. Yilmaz
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Roles of PPARs in NAFLD: Potential therapeutic targets
Anne Tailleux et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2012)
Nuclear Receptors Reverse McGarry's Vicious Cycle to Insulin Resistance
David D. Moore
CELL METABOLISM (2012)
Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis
Feng Zhang et al.
CELLULAR SIGNALLING (2012)
The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells
L. Serrano-Marco et al.
DIABETOLOGIA (2012)
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
G. Musso et al.
DIABETOLOGIA (2012)
Genetic Variation in the Peroxisome Proliferator Activated Receptor-Gamma Gene Is Associated with Histologically Advanced NAFLD
Samer Gawrieh et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
Mi Young Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2012)
Sterile Inflammation in the Liver
Paul Kubes et al.
GASTROENTEROLOGY (2012)
Consumption of n-3 Fatty Acids and Fish Reduces Risk of Hepatocellular Carcinoma
Norie Sawada et al.
GASTROENTEROLOGY (2012)
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Naga Chalasani et al.
GASTROENTEROLOGY (2012)
Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study
Yin-Mei Lee et al.
GASTROINTESTINAL ENDOSCOPY (2012)
Coordinate regulation of neutrophil homeostasis by liver X receptors in mice
Cynthia Hong et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Peroxisome proliferator-activated receptor-α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis
Claire Z. Larter et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Potential for statins in the chemoprevention and management of hepatocellular carcinoma
Amedeo Lonardo et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Phenotyping the effect of diet on non-alcoholic fatty liver disease
Nicole J. W. de Wit et al.
JOURNAL OF HEPATOLOGY (2012)
Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up
Shira Zelber-Sagi et al.
JOURNAL OF HEPATOLOGY (2012)
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies
Ahmad Al-Serri et al.
JOURNAL OF HEPATOLOGY (2012)
Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Shelley E. Keating et al.
JOURNAL OF HEPATOLOGY (2012)
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Helen M. Parker et al.
JOURNAL OF HEPATOLOGY (2012)
Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication
Maria Victoria Garcia-Mediavilla et al.
LABORATORY INVESTIGATION (2012)
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States
Zobair M. Younossi et al.
MEDICINE (2012)
Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects
M. C. E. Bragt et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2012)
N-3 Long-Chain Polyunsaturated Fatty Acid Supplementation Significantly Reduces Liver Oxidative Stress in High Fat Induced Steatosis
Rodrigo Valenzuela et al.
PLOS ONE (2012)
PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs
Marion Peyrou et al.
PPAR RESEARCH (2012)
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
Laurent Azoulay et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease
S. Petta et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT
Cris A. Slentz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2011)
Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?
Vasilios G. Athyros et al.
ANNALS OF MEDICINE (2011)
Peroxisome Proliferator-Activated Receptor-α Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice
Fanny Lalloyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia
Mario Claudio Soares Sturzeneker et al.
ATHEROSCLEROSIS (2011)
The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats
Su Liu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts
Eva Moran-Salvador et al.
FASEB JOURNAL (2011)
Liver X Receptor Signaling Is a Determinant of Stellate Cell Activation and Susceptibility to Fibrotic Liver Disease
Simon W. Beaven et al.
GASTROENTEROLOGY (2011)
Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient
Gerald F. Watts et al.
HEART (2011)
Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis in Humans: A 12-Month Randomized, Prospective, Open-Label Trial
Dawn M. Torres et al.
HEPATOLOGY (2011)
Pharmacological Activation of Peroxisome Proliferator-activated Receptor δ Improves Insulin Resistance and Hepatic Steatosis in High Fat Diet-induced Diabetic Mice
H. -T. Wu et al.
HORMONE AND METABOLIC RESEARCH (2011)
Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation
Sihao Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
Harold E. Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction
Paulina Pettinelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
The role of thiazolidinediones in non-alcoholic steatohepatitis - A systematic review and meta analysis
Suzanne E. Mahady et al.
JOURNAL OF HEPATOLOGY (2011)
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2011)
PPARα Expression Protects Male Mice from High Fat-Induced Nonalcoholic Fatty Liver
Mohamed A. Abdelmegeed et al.
JOURNAL OF NUTRITION (2011)
An increase in liver PPARγ2 is an initial event to induce fatty liver in response to a diet high in butter: PPARγ2 knockdown improves fatty liver induced by high-saturated fat
Tomomi Yamazaki et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2011)
Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?
Amedeo Lonardo et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of 'multiorganelle failure'? Proceedings of a virtual workshop on nonalcoholic steatohepatitis Foreword
Amedeo Lonardo et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Hepatotoxicity Fears Contribute to Underutilization of Statin Medications by Primary Care Physicians
Fadi S. Rzouq et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2010)
Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome - An allostatic perspective
Sam Virtue et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2010)
Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
Paola Dongiovanni et al.
BMC GASTROENTEROLOGY (2010)
From the metabolic syndrome to NAFLD or vice versa?
Ester Vanni et al.
DIGESTIVE AND LIVER DISEASE (2010)
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee
P. Loria et al.
DIGESTIVE AND LIVER DISEASE (2010)
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years
Vincent Wai-Sun Wong et al.
GUT (2010)
Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial
Vlad Ratziu et al.
HEPATOLOGY (2010)
High-Dose Ursodeoxycholic Acid Therapy for Nonalcoholic Steatohepatitis: A Double-Blind, Randomized, Placebo-Controlled Trial
Ulrich F. H. Leuschner et al.
HEPATOLOGY (2010)
Rosiglitazone Attenuates Age- and Diet-Associated Nonalcoholic Steatohepatitis in Male Low-Density Lipoprotein Receptor Knockout Mice
Anisha A. Gupte et al.
HEPATOLOGY (2010)
The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis
Mustafa S. Ascha et al.
HEPATOLOGY (2010)
Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro
Jun Yu et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Activation of Liver X Receptor Sensitizes Human Dendritic Cells to Inflammatory Stimuli
Daniel Torocsik et al.
JOURNAL OF IMMUNOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Transcriptional profiling reveals divergent roles of PPARα and PPARβ/δ in regulation of gene expression in mouse liver
Linda M. Sanderson et al.
PHYSIOLOGICAL GENOMICS (2010)
Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts
Peter Fickert et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: Correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion
Paulina Pettinelli et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2009)
Hepatocellular Carcinoma in Patients With Cryptogenic Cirrhosis
Edoardo Giovanni Giannini et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis
L. Carulli et al.
DIGESTIVE AND LIVER DISEASE (2009)
Hepatocellular Carcinomas in Patients With Metabolic Syndrome Often Develop Without Significant Liver Fibrosis: A Pathological Analysis
Valerie Paradis et al.
HEPATOLOGY (2009)
Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis
Amalia Gastaldelli et al.
HEPATOLOGY (2009)
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Philippe Lefebvre et al.
PHYSIOLOGICAL REVIEWS (2009)
Bile acids: Chemistry, physiology, and pathophysiology
Maria J. Monte et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance
Justin I. Odegaard et al.
CELL METABOLISM (2008)
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
C. Fernandez-Miranda et al.
DIGESTIVE AND LIVER DISEASE (2008)
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial
Vlad Ratziu et al.
GASTROENTEROLOGY (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes
Anna Ludovica Fracanzani et al.
HEPATOLOGY (2008)
Peroxisome proliferator-activated receptor-δ induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice
Xiaomei Qin et al.
HEPATOLOGY (2008)
A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio
Shaohua Chen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome
Dorninique Roulot et al.
JOURNAL OF HEPATOLOGY (2008)
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet
Mary E. Rinella et al.
JOURNAL OF LIPID RESEARCH (2008)
Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets
Jacob George et al.
MOLECULAR PHARMACEUTICS (2008)
Bariatric Therapy with Intragastric Balloon Improves Liver Dysfunction and Insulin Resistance in Obese Patients
Giorgio Ricci et al.
OBESITY SURGERY (2008)
Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia
Feng-Shang Zhu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men
Ulf Riserus et al.
DIABETES (2008)
Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis
Deepak Kumar Singh et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats
Jorge E. Toblli et al.
OBESITY (2008)
Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice
Weiwei Shan et al.
HEPATOLOGY (2008)
Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet
Haiyan Jin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats
Koji Fujita et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects
Jukka Westerbacka et al.
DIABETES (2007)
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
Bogdan Balas et al.
JOURNAL OF HEPATOLOGY (2007)
Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy
Tao Jiang et al.
DIABETES (2007)
Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Ja-Young Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Glen Lutchman et al.
HEPATOLOGY (2007)
Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
M. Bajaj et al.
DIABETOLOGIA (2007)
Impact of statin dosing intensity on transaminase and creatine kinase
Krista M. Dale et al.
AMERICAN JOURNAL OF MEDICINE (2007)
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer - Insights from large randomized statin trials
Alawi A. Alsheikh-Ali et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis
Patricio Ibanez et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Angiotensin II type I receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis
Akira Hirose et al.
HEPATOLOGY (2007)
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
Kanji Yamaguchi et al.
HEPATOLOGY (2007)
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis
Jean-Francois Dufour et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver
Yuichi Harano et al.
LIVER INTERNATIONAL (2006)
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
Vasilios G. Athyros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet
T Nagasawa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study
M Capanni et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates
R Shiri-Sverdlov et al.
JOURNAL OF HEPATOLOGY (2006)
Liver X receptors as integrators of metabolic and inflammatory signaling
N Zelcer et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Peroxisome proliferator-activated receptor α mediates the effects of high-fat diet on hepatic gene expression
D Patsouris et al.
ENDOCRINOLOGY (2006)
PPARδ regulates glucose metabolism and insulin sensitivity
CH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Review article: hepatic steatosis and insulin resistance
A Lonardo et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Increased expression of PPARγ in high fat diet-induced liver steatosis in mice
M Inoue et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation
M Nakamuta et al.
TRANSPLANTATION (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
PPARγ-mediated insulin sensitization:: the importance of fat versus muscle
U Kintscher et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice
E Ip et al.
HEPATOLOGY (2004)
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
KD Lindor et al.
HEPATOLOGY (2004)
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease
A Lonardo et al.
GASTROENTEROLOGY (2004)
A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis
K Promrat et al.
HEPATOLOGY (2004)
Relative contribution of iron burden, HFE mutation and insulin resistance to fibrosis in nonalcoholic fatty liver
E Bugianesi et al.
HEPATOLOGY (2004)
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis
S Fiorucci et al.
GASTROENTEROLOGY (2004)
Peroxisome proliferator-activated receptor β/δ regulates very low density lipoprotein production and catabolism in mice on a Western diet
TE Akiyama et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice
E Ip et al.
HEPATOLOGY (2003)
Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma
E Bugianesi et al.
GASTROENTEROLOGY (2002)
Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
JB Dixon et al.
GASTROENTEROLOGY (2001)
Share Paper
